C OSBORNE to Cell Line, Tumor
This is a "connection" page, showing publications C OSBORNE has written about Cell Line, Tumor.
Connection Strength
0.091
-
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). Cancer J Sci Am. 1996 May-Jun; 2(3):175-80.
Score: 0.018
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.016
-
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006 Dec; 10(6):487-99.
Score: 0.009
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.009
-
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
Score: 0.009
-
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
Score: 0.008
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.008
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.007
-
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther. 2002 Dec; 6(6):783-92.
Score: 0.007